Urinary false-positive ecstasy screening by Mebeverine Metabolite: a confirmatory study and controlled administration.

Authors

Bounab Moncef, Mechalikh Rahima Tassadit, Boussebt Cheima, Ettaieb Errahmani Salima, Kaddour Salma

Published in

Acta clinica Belgica. Pages 1-9. Sep 07, 2026. Epub Sep 07, 2026.

Abstract

Urinary immunochromatographic tests (ICTs) are first-line tools for psychoactive substance screening in clinical and forensic settings. Their limited specificity, however, predisposes them to cross-reactive interferences generating false-positive results.We report three consecutive cases of false-positive 3,4-methylenedioxymethamphetamine (MDMA) results on rapid urinary ICT screening attributable to therapeutic mebeverine use, all confirmed by gas chromatography-mass spectrometry (GC-MS). Three patients admitted to emergency and intensive care units were all receiving mebeverine therapeutically.A 12-panel ICT (MDMA cut-off: 500 ng/mL) returned presumptive positive MDMA results in all three specimens. GC-MS confirmatory analysis detected neither MDMA nor its primary metabolite, 3,4-methylenedioxyamphetamine (MDA). Mebeverine O-desmethyl-butanol was consistently identified in all three specimens. A spiking experiment with certified mebeverine hydrochloride at 3000 ng/mL yielded a negative ICT result, excluding the parent compound as the causative agent. A controlled single-dose administration experiment (200 mg oral mebeverine) produced positive MDMA ICT results in all four urine specimens collected between 4 and 13 hours post-ingestion; GC-MS confirmed mebeverine O-desmethyl-butanol as the sole mebeverine-derived compound identified, strongly implicating this metabolite in the observed cross-reactivity.Any positive MDMA immunochromatographic result in a patient receiving mebeverine must be confirmed by GC-MS or LC-MS/MS. Mebeverine and its metabolites should be incorporated into cross-reactivity documentation by ICT manufacturers.

PMID:
42704114
Bibliographic data and abstract were imported from PubMed on 07 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.